Skip to main content
Livermore
Livermore
ZHEN

Morgan Stanley

SEC CIK
0000895421
Latest filing
Aug 13, 2026

KALV holding history

KalVista Pharmaceuticals, Inc. in every 13F filed by Morgan Stanley, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

KALV overviewAll 13F holders of KALVFull Q2 2026 holdings

Shares (Q2 2026)
0
Sold out in Q2 2026
Value
$0
% of portfolio
0.0%
Quarters held
21
Since Q1 2021
Holdings of KALV by Morgan Stanley, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20260$00.0%−439,099−100.0%Sold outHolders
Q1 2026439,099$8.84M<0.1%−261,129−37.3%ReducedHolders
Q4 2025700,228$11.3M<0.1%+135,372+24.0%AddedHolders
Q3 2025564,856$6.88M<0.1%+325,227+135.7%AddedHolders
Q2 2025239,629$2.71M<0.1%+15,840+7.1%AddedHolders
Q1 2025223,789$2.58M<0.1%−65,726−22.7%ReducedHolders
Q4 2024289,515$2.45M<0.1%−7,887−2.7%ReducedHolders
Q3 2024297,402$3.44M<0.1%−41,182−12.2%ReducedHolders
Q2 2024338,584$3.99M<0.1%−85,850−20.2%ReducedHolders
Q1 2024424,434$5.03M<0.1%−28,000−6.2%ReducedHolders
Q4 2023452,434$5.54M<0.1%+242,506+115.5%AddedHolders
Q3 2023209,928$2.02M<0.1%+7,305+3.6%AddedHolders
Q2 2023202,623$1.82M<0.1%+10,847+5.7%AddedHolders
Q1 2023191,776$1.51M<0.1%−641,977−77.0%ReducedHolders
Q4 2022833,753$5.64M<0.1%+802,871+2,599.8%AddedHolders
Q3 202230,882$448.0K<0.1%−28,437−47.9%ReducedHolders
Q2 202259,319$584.0K<0.1%−8,060−12.0%ReducedHolders
Q1 202267,379$993.0K<0.1%+4,295+6.8%AddedHolders
Q4 202163,084$835.0K<0.1%+45,963+268.5%AddedHolders
Q3 202117,121$300.0K<0.1%+7,306+74.4%AddedHolders
Q2 20219,815$235.0K<0.1%−20,000−67.1%ReducedHolders
Q1 202129,815$766.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.